Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled Trial, to Evaluate the Safety, Immunogenicity and the Optimal Dose of MOPEVAC-Las Vaccine Candidate Against Lassa Fever, in Healthy Volunteers Consisting of an Unblinded Dose Escalation and a Blinded Treatment Phase

NCT07833436 is registered in ClinicalTrials.gov with Institut Pasteur as lead sponsor.

NCT NCT07833436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07833436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled Trial, to Evaluate the Safety, Immunogenicity and the Optimal Dose of MOPEVAC-Las Vaccine Candidate Against Lassa Fever, in Healthy Volunteers Consisting of an Unblinded Dose Escalation and a Blinded Treatment Phase
Lead sponsor
Institut Pasteur
Phase
Phase 1
Overall status
Recruiting
Start date
September 28, 2026
Completion date
December 31, 2028
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lassa fever